Georgia's Online Cancer Information Center

Find A Treatment Site

Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center

The Curtis and Elizabeth Anderson Cancer Institute (ACI) at Memorial University Medical Center, is a cancer center in Savannah, Georgia. Memorial Health is accredited by the Commission on Cancer of the American College of Surgeons as a Teaching Hospital Cancer Program. The center is a recipient of the Georgia Cancer Coalition Distinguished Cancer Scholars Award, which supports leaders who are engaged in the most promising areas of cancer research. Memorial Health is a member of the Georgia CORE Research Network, a statewide network of academic and community-based oncologists and researchers and a member of the Georgia CORE Gynecologic Oncology Group Consortium. The center consists of 32 physicians, including two radiation oncologists. Memorial Health offers a state-of-the-art research laboratory, leading-edge technology and compassionate support programs. They offer the following services: community support groups, educational programs, insurance assistance, resource room, oncology interdisciplinary care, coordination team, oncology social workers, patient advocacy, support line, wellness services, spiritual care and pediatric services.

Treatment Sites in Georgia

Clinical Trials in Georgia

A Phase 2 Randomized Study of Irinotecan / Temozolomide / Dinutuximab with or without Eflornithine (DFMO) in Children with Relapsed, Refractory or Progressive Neuroblastoma
Cancer Type: Neuroblastoma

A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged = 1 to < 31 Years Old with First Relapse
Cancer Type: Unspecified

A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Cancer Type: Unspecified

A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Cancer Type: Lymphoma

A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Cancer Type: Unspecified

A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations
Cancer Type: Unspecified

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Cancer Type: Unspecified

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL)
Cancer Type: Neuroblastoma

A Phase 3 Trial Investigating Blinatumomab ( NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
Cancer Type: Lymphoma

A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent Endometrioid / Clear Cell Carcinoma of the Ovary or Peritoneum, and Recurrent Low Grade Endometrioid Endometrial Adenocarcinoma
Cancer Type: Endometrial Cancer, Ovarian Cancer

A Phase III, Randomized Study of Nivolumab (Opdivo) plus AVD or Brentuximab Vedotin (Adcetris) plus AVD in Patients (Age > / = 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Cancer Type: Lymphoma

A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®) in Combination Versus PLD in Participants With Platinum-Resistant Ovarian Cancer
Cancer Type: Ovarian Cancer

A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC) - The STABLE-MATES Trial
Cancer Type: Lung Cancer

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Cancer Type: Breast Cancer

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Eye Cancer, Lymphoma, Multiple Primaries, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary

Improving Surgical Care and Outcomes in Older Cancer Patients through Implementation of an Efficient Pre-Surgical Toolkit (OPTI-Surg)
Cancer Type: Unspecified

International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
Cancer Type: Lymphoma

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II / III Randomized Study of Chemoradiation versus Chemoradiation plus Atezolizumab
Cancer Type: Lung Cancer, Skin Cancer (Non-Melanoma)

National Wilm's Tumor Study Late Effects
Cancer Type: Wilms Tumor

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients with Tumors Harboring RET Gene Alterations
Cancer Type: Unspecified

NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of Ly3023414 in Patients with Solid Tumors
Cancer Type: Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Unknown Primary

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Cancer Type: Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Unknown Primary

NSABP Patient Registry and Biospecimen Profiling Repository
Cancer Type: Colon/Rectal Cancer

Phase III Randomized Study of Adjuvant Radiation Versus Chemoradiation Therapy in Patients With Intermediate-Risk Stage I-IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy
Cancer Type: Cervical Cancer

Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiotherapy With Versus Without Adjuvant Chemotherapy in Patients With High-Risk Early-Stage Cervical Carcinoma After Radical Hysterectomy
Cancer Type: Cervical Cancer

Pilot Study of Neuropsychological and Behavioral Assessment in Children With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)
Cancer Type: Brain Cancer

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
Cancer Type: Lung Cancer

Research Study of Clinical, Genetic, and Biological Factors as Prognostic Values in Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
Cancer Type: Neuroblastoma

Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Cancer Type: Acute Myelogenous Leukemia

Study of Renal Tumors in Pediatric Patients
Cancer Type: Kidney Cancer

Targeted Intraoperative Radiotherapy United States (TARGIT-US) Phase IV Registry Trial: A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-conserving Surgery
Cancer Type: Breast Cancer

Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Cancer Type: Unspecified

Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-high-Risk Neuroblastoma: A Groupwide Historically Controlled Phase III Study
Cancer Type: Neuroblastoma
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.
Georgia CORE


Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofitthat leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.